
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics has demonstrated significant growth potential, with a dramatic increase in the projected 4Q revenue to $16.2 million, boosted by a greater than 40% increase in prescription volumes in October. This growth is linked to an increase in the number of prescriptions written, with the company reporting a 41% sequential rise in October, exceeding the total volume from the previous quarter in just the first seven weeks of 4Q. Additionally, the expansion of the sales force from 50 to 64 territory managers aims to enhance clinician coverage from approximately 8,000 to 10,000, positioning Pelthos for greater market penetration and revenue growth in the coming year.
Bears say
Pelthos Therapeutics faces significant challenges that contribute to a negative outlook for its stock. Specifically, the company may struggle with market penetration and revenue growth due to potential issues with reimbursement, formulary placement, and adoption by key healthcare providers. Additionally, competitive pressures from alternative therapies and risks associated with clinical trials, funding, and operational execution could further hinder the company’s ability to achieve its projected financial performance.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares